Related Experiment Videos
Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle
1Dipartimento di Fisiologia e Biochimica Generali, Università degli Studi di Milano, Italy.
Abstract:
We have investigated the effects on Saccharomyces cerevisiae of a novel antitumour agent (FCE24517 or Tallimustine) which causes selective alkylations to adenines in the minor groove of DNA. Tallimustine, added to wild-type cells for short periods, reduced the growth rate and increased the percentage of budded cells and delayed the cell cycle in the late S + G2 + M phases. In the rad9 delta null mutant cells, Tallimustine treatment did not affect growth rate and the percentage of budded cells but greatly reduced cell viability compared to isogenic cells. Consistent with a role of RAD9 in inducing a transient delay in G2 phase which preserves cell viability, the potent cytotoxic effect of the drug on rad9 delta cells was alleviated by treatment with nocodazole. Tallimustine was also found to delay the resumption from G1 arrest of wild-type but not of rad9 delta cells. These data indicate that the effects of Tallimustine on cell cycle progression in yeast are mediated by the RAD9 gene product. From our data it appears that yeast could be a valuable model system to study the mode of action of this alkylating drug and of minor groove alkylators in general.
Insights
The novel antitumor agent Tallimustine selectively alkylates DNA. In yeast, Tallimustine
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- A novel antitumor agent, FCE24517 (Tallimustine), selectively alkylates DNA.
- Minor groove alkylators represent a class of compounds with potential therapeutic applications.
Purpose of the Study:
- To investigate the effects of Tallimustine on Saccharomyces cerevisiae.
- To elucidate the role of the RAD9 gene in mediating Tallimustine's cellular effects.
Main Methods:
- Treatment of wild-type and rad9 delta null mutant Saccharomyces cerevisiae with Tallimustine.
- Cell cycle analysis, including growth rate, percentage of budded cells, and cell cycle phase progression.
- Assessment of cell viability following drug treatment and cell cycle arrest.
Main Results:
- Tallimustine reduced growth rate and delayed cell cycle progression in wild-type yeast.
- In rad9 delta mutants, Tallimustine significantly reduced cell viability without affecting growth rate or budded cell percentage.
- The cytotoxic effects of Tallimustine on rad9 delta cells were mitigated by nocodazole treatment, and G1 arrest resumption was only delayed in wild-type cells.
Conclusions:
- The RAD9 gene product mediates the effects of Tallimustine on cell cycle progression in yeast.
- Saccharomyces cerevisiae serves as a valuable model system for studying the mechanism of action of Tallimustine and similar minor groove alkylating drugs.